Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Liabilities and Shareholders Equity (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $352.4 million in Q2 2025.

  • For Q2 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $352.4 million; the TTM value through Dec 2025 reached $696.5 million, down 11.41%, while the annual FY2024 figure was $348.9 million, 2.2% up from the prior year.
  • Liabilities and Shareholders Equity reached $352.4 million in Q2 2025 per ARQT's latest filing, up from $344.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $508.9 million in Q3 2022 and bottomed at $293.0 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $379.6 million, with a median of $364.1 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 95.45% in 2021, then plummeted 42.43% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $408.2 million in 2021, then increased by 10.08% to $449.3 million in 2022, then fell by 24.02% to $341.4 million in 2023, then grew by 2.2% to $348.9 million in 2024, then increased by 1.02% to $352.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $352.4 million in Q2 2025, $344.1 million in Q1 2025, and $348.9 million in Q4 2024.